Sab Biotherapeutics Inc (SABS)

Sab Biotherapeutics Inc Azioni (SABS) Dati Finanziari

Conto economico

Trimestrale

*Tutti i numeri sono espressi in milioni

Data di fine periodo	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Durata del periodo	3 mesi	3 mesi	3 mesi	3 mesi	3 mesi
Revenues	209.69% 0.9446	0.305	1.2674	0.0855	0.5811
Operating Expenses	35.68% 12.34	19.18	6.5903	6.5621	7.9831
Interest Income/Expense	1.94% 0.0764	0.0779	0.0697	0.0753	0.0924
Benefits Costs and Expenses	74.22% 5.9703	23.16	6.3697	6.9664	7.9349
Costs And Expenses	74.22% 5.9703	23.16	6.3697	6.9664	7.9349
Operating Income/Loss	39.65% -11.39	-18.87	-5.3229	-6.4766	-7.402
Nonoperating Income/Loss	259.80% 6.3649	-3.983	0.2206	-0.4043	0.0482
Income/Loss From Continuing Operations Before Tax	78.01% -5.0257	-22.86	-5.1023	-6.8809	-7.3538
Income/Loss From Continuing Operations After Tax	78.01% -5.0257	-22.86	-5.1023	-6.8809	-7.3538
Net Income/Loss	78.01% -5.0257	-22.86	-5.1023	-6.8809	-7.3538
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	120.28% 9.2419	-45.56	52.41	50.42	50.40
Diluted Average Shares	120.28% 9.2419	-45.56	52.41	-	50.40
Basic Earnings Per Share	92.56% -0.54	-7.26	-0.10	-0.14	-0.15
Diluted Earnings Per Share	92.56% -0.54	-7.26	-0.10	-	-0.15
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-